PRESS RELEASE published on 02/17/2024 at 01:50, 1 year 11 months ago BioNxt Solutions Finalizes Agreement BioNxt Solutions Inc. finalizes Settlement Agreement with a creditor to settle $282,415 debt through issuance of common shares and a cash payment. Debt to be settled in three instalments of shares based on market price Common Shares Debt Settlement BioNxt Solutions Inc. Settlement Agreement Creditor
PRESS RELEASE published on 01/30/2024 at 05:48, 2 years ago BIONXT SOLUTIONS ANNOUNCES CLOSING OF FINAL TRANCHE OF NON-BROKERED PRIVATE PLACEMENT BioNxt Solutions Inc. closes final tranche of non-brokered private placement, raising gross proceeds of $288,000 to fund drug development and working capital purposes Private Placement Working Capital Investment Drug Development BioNxt Solutions Inc.
PRESS RELEASE published on 12/22/2023 at 09:05, 2 years 1 month ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/22/2023 at 01:50, 2 years 1 month ago BioNxt Solutions Announces Completion of Cladribine ODF Toxicity Study and Financing
PRESS RELEASE published on 12/12/2023 at 09:05, 2 years 1 month ago BioNxt Receives Delivery of Premium Commercial Coating and Cutting Equipment for Commercial Manufacturing of Drug Delivery Products
PRESS RELEASE published on 12/09/2023 at 04:30, 2 years 1 month ago BioNxt Solutions Announces Completion of Debenture and Interest Settlement and Issuance of Finder’s Warrants
PRESS RELEASE published on 11/25/2023 at 01:44, 2 years 2 months ago Bionxt Solutions Announces Convertible Debenture and Interest Settlement
PRESS RELEASE published on 11/20/2023 at 09:05, 2 years 2 months ago BioNxt Accelerates Cladribine ODF Clinical and Commercialization Strategy for Multiple Sclerosis Treament
PRESS RELEASE published on 11/15/2023 at 09:05, 2 years 2 months ago BioNxt Reports on New Cladrabine ODF Product Development and Commercialization Program
PRESS RELEASE published on 11/13/2023 at 09:05, 2 years 2 months ago BioNxt Signs Definitive Agreement For 100% Acquisition of IP And Co-Development of Cladribine ODF Drug Reformulation for The Treatment of Multiple Sclerosis
Published on 01/30/2026 at 08:35, 2 hours 1 minute ago Alaska Energy Metals Announces Closing Of Life Offering of Units
Published on 01/30/2026 at 08:00, 2 hours 36 minutes ago Troubadour Resources Intercepts Target Mineralization Near Surface during Phase 1 of the Multi-Phase Drill Program at Senneville Gold-Silver-Copper Property
Published on 01/30/2026 at 02:15, 8 hours 21 minutes ago Canex Metals Announces Success of Gold Basin Take-Over Bid, Extension of the Partial Revocation of the Cease-Trade Order Imposed on Gold Basin, Waiver of All Remaining Conditions, Initiation of the Share Take Up Process, and Mandatory 10-Day Extension
Published on 01/30/2026 at 00:00, 10 hours 36 minutes ago LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies
Published on 01/29/2026 at 23:00, 11 hours 36 minutes ago PPX Mining Announces Filing of 2025 Audited Financial Statements and MD&A
Published on 01/30/2026 at 09:00, 1 hour 35 minutes ago Original-Research: 123fahrschule SE (von NuWays AG): BUY
Published on 01/30/2026 at 09:00, 1 hour 35 minutes ago Original-Research: q.beyond AG (von NuWays AG): BUY
Published on 01/29/2026 at 18:00, 16 hours 36 minutes ago GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 16 hours 51 minutes ago LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 16 hours 51 minutes ago Cegedim generated LFL revenue growth of 1.1% in 2025
